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Abstract
Objective To determine the comparative effectiveness and safety of
current maintenance strategies in preventing exacerbations of asthma.
Design Systematic review and network meta-analysis using Bayesian
statistics.
Data sources Cochrane systematic reviews on chronic asthma,
complemented by an updated search when appropriate.
Eligibility criteria Trials of adults with asthma randomised to
maintenance treatments of at least 24 weeks duration and that reported
on asthma exacerbations in full text. Low dose inhaled corticosteroid
treatment was the comparator strategy. The primary effectiveness
outcome was the rate of severe exacerbations. The secondary outcome
was the composite of moderate or severe exacerbations. The rate of
withdrawal was analysed as a safety outcome.
Results 64 trials with 59 622 patient years of follow-up comparing 15
strategies and placebo were included. For prevention of severe
exacerbations, combined inhaled corticosteroids and long acting β
agonists as maintenance and reliever treatment and combined inhaled
corticosteroids and long acting β agonists in a fixed daily dose performed
equally well and were ranked first for effectiveness. The rate ratios
compared with low dose inhaled corticosteroids were 0.44 (95% credible
interval 0.29 to 0.66) and 0.51 (0.35 to 0.77), respectively. Other
combined strategies were not superior to inhaled corticosteroids and all
single drug treatments were inferior to single low dose inhaled
corticosteroids. Safety was best for conventional best (guideline based)
practice and combined maintenance and reliever therapy.
Conclusions Strategies with combined inhaled corticosteroids and long
acting β agonists are most effective and safe in preventing severe
exacerbations of asthma, although some heterogeneity was observed
in this network meta-analysis of full text reports.
Introduction
Asthma is a widespread chronic airway disease characterised
by an unpredictable course.1 Preventing exacerbations is
considered a major long term treatment goal in international
guidelines.1These episodes of sudden deterioration of symptoms
and airways obstruction result in a burden to the patient and use
of expensive medical resources. Asthma related healthcare
expenses in patients with exacerbations are double ($1740
(£1035; €1257) v $847) those of patients without
exacerbations.2 3
Although inhaled corticosteroids—anti-inflammatory controller
drugs—are currently the cornerstone of preventing asthma
exacerbations,4-6 several other agents or combination strategies
Correspondence to: R J B Loymans r.j.loijmans@amc.nl
Extra material supplied by the author (see http://www.bmj.com/content/348/bmj.g3009?tab=related#webextra)
Table S1: data from included studies
Table S2: risk of bias assessment of included studies
Table S3: reported harms in included studies
Figure S1: analysis with non-imputed data
Figure S2: sensitivity analyses for severe exacerbations
Figure S3: funnel plots of direct comparisons with five or more studies, for severe exacerbations
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;348:g3009 doi: 10.1136/bmj.g3009 (Published 13 May 2014) Page 1 of 16
Research
RESEARCH
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
53
51
2 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7
have been investigated.7 Such strategies include combinations
of existing agents, such as inhaled corticosteroids and long
acting β agonists,8-10 and other agents, such as leukotriene
receptor antagonists11 and anti-IgE antibodies,12 which have
been tested in multiple clinical trials.
Previous research syntheses on the effectiveness of different
strategies in asthma have been informative but have drawbacks,
such as only comparing pairs of strategies, non-standardised
definitions of drug dosages and outcomes, and inclusion of
mainly trials with a follow-up of less than 20 weeks.13 14 Hence
amore standardised comparison of all relevant drugmaintenance
strategies to prevent asthma exacerbations is needed. Network
meta-analysis (also called multiple treatment comparison) is a
relatively new approach that uses all available evidence and
formally compares all existing strategies.15 16
We determined the comparative effectiveness and safety of all
available maintenance treatment strategies for chronic asthma
for their ability to reduce consistently defined exacerbations
during long term treatment, and to rank them for these outcomes.
We carried out a network meta-analysis of drug interventions
to prevent exacerbations in patients with persistent asthma, in
trials of at least 24 weeks’ duration, and with exacerbations
defined according to the American Thoracic Society/European
Respiratory Society.17
Methods
Systematic review and data extraction
To identify randomised controlled trials we assessed all
Cochrane systematic reviews on chronic asthma (http://airways.
cochrane.org/our-reviews) published before 1 August 2011 and
selected the 16 on drug interventions in adults.18-33 We assessed
all studies included in these reviews, as well as those that were
listed as having been rejected by the Cochrane authors. We
carried out an update search for all reviews using the identical
search terms reported in these reviews. This search was
performed on 1 August 2013 in the Cochrane Airways Group
register of trials, which consists, among others, of trials on
asthma inMedline, Embase, and the Cochrane Central Register
of Controlled Trials (http://airways.cochrane.org/trials-register).
We screened all references of included reports for eligible trials.
Eligible reports were full text randomised controlled trials lasting
at least 24 weeks that compared different drug strategies for the
maintenance treatment of asthma in adults and reported on
exacerbations. We applied no restrictions on language or
publication date. For an intervention to be included in the
analysis, it had to be evaluated in at least two separate trials.
One investigator removed all reports that were not full text
publications and reports on interventions lasting less than 24
weeks. Two investigators independently assessed all remaining
reports on title and abstract. The full text of those remaining
was assessed against the inclusion criteria. Two investigators
(RL and JC) used standardised forms to independently extract
data on the characteristics of publication, patients, intervention,
outcomes, and risk of bias. We assessed risk of bias from
selection, performance, attrition, detection, and selective
reporting according to recommendations in the Cochrane
handbook.34 Differences were resolved by agreement, after
which we entered data in a database using a dedicated entry
screen. To screen for publication bias we created funnel plots
for all direct comparisons yielding five or more studies. We
emailed the corresponding authors for missing data on outcomes.
After data extraction, we evaluated studies against the similarity
assumptions required for network meta-analysis—that is, the
extent to which covariates, such as patient characteristics, that
would act as modifiers of relative treatment effect were similar
across studies.35 For this reason we included only full text
reports: abstracts presented at conferences and from
manufacturer’s websites do not contain sufficient information
on patient characteristics, methods, and quality to assess whether
similarity assumptions are met. Also, we omitted trials on
tailored strategies with monoclonal antibodies or maintenance
treatment with systemic corticosteroids, since these strategies
are only used for specific patient phenotypes with severe asthma.
Measuring treatment effect
Given the known wide variation in definitions of asthma
exacerbations in the literature,17we created standardised criteria
for moderate and severe exacerbations before data extraction
that were consistent with American Thoracic Society/European
Respiratory Society recommendations.17 If a report defined
exacerbations as hospital admission, visit to an emergency
department, or prescription of systemic corticosteroids for at
least three days, we classified the events as severe exacerbations.
We classified events as moderate exacerbations if they were
defined by a decrease in pulmonary function (peak flow or
forced expiratory volume), increased use of rescue drugs, or
night time waking because of asthma symptoms (all for at least
two consecutive days), or by unscheduled visits to or by a
doctor. Unless the report stated that most events fulfilled the
criteria for severe exacerbations, we classified events defined
by elements of both severe and moderate exacerbations as
moderate exacerbations.
We converted all doses of inhaled corticosteroids into dose
equivalents of beclometasone by multiplying with conversion
factors1: 1.0 for beclometasone with chlorofluorocarbon
propellant, 2.0 for beclometasone with hydrofluoroalkane
propellant, 1.25 for budesonide chlorofluorocarbon, 1.25 for
budesonide hydrofluoroalkane, 3.15 for ciclesonide
chlorofluorocarbon, 6.3 for ciclesonide hydrofluoroalkane, 0.5
for flunisolide, 2.0 for fluticasone propionate, 1.25 for
mometasone, and 0.5 for triamcinolone, with a threshold of 500
µg beclometasone chlorofluorocarbon a day to discriminate low
doses from medium or high doses. We regarded fluticasone
propionate 2.5 as equipotent to fluticasone fuorate 1.0 according
to the manufacturer’s summary of product characteristics. Trial
arms with similar strategies in a single trial were included and
analysed as one—for example, if two arms had different doses
of inhaled corticosteroids in the same (low or high) dose range,
we classified both as either high or low dose.
In asthma literature, exacerbations are commonly reported as
the number of events per trial arm, the proportion of patients
with at least one exacerbation, or exacerbation rates (numbers
per person time of follow-up). We calculated rates per trial arm
from the numbers of exacerbations and patient years; the
numbers of patient years were estimated by multiplying the
number of patients by the intended follow-up time, assuming
that patients who withdrew during the intervention had done so
halfway through the trial. If numbers of exacerbations were not
available, we used the reported exacerbation rates, and we
distinguished between rates weighted by follow-up duration
and those not weighted, since non-weighted rates tend to yield
exaggerated effect estimates.36 37 If numbers of patients with
exacerbations were only reported, we imputed the number of
exacerbations with estimations using median regression with
linear and quadratic terms of numbers of patients with
exacerbations and patient years as covariates.
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Measuring safety
Owing to the wide variation in reporting of adverse events, we
analysed reported withdrawals as a result of adverse events as
the primary safety variable. These rates were reported in most
studies, varied little in definition, and were considered most
likely to reflect the reasons for decisions to withdraw. As a
secondary safety outcome we analysed the total number of
withdrawals.
Statistical analysis
We used Bayesian hierarchical random effects models,38 fully
preserving randomised treatment effects within trials and
accounting for correlation between comparisons withinmultiarm
trials.39 Adjusting for patient years under all situations, we used
a log-linear Poisson model (exacerbation rate ratios) to analyse
the number of exacerbations and a logistic model (odds ratios)
with complementary log-log link function to analyse the
numbers of patients with at least one exacerbation and the
number of study withdrawals. We fitted models with Markov
chain Monte Carlo simulations with non-informative priors.15
Pooled rate ratios were estimated from the median of the
posterior distribution of the difference in risk estimate between
two treatments and corresponding 95% credible intervals
derived. For each strategy we estimated the probability of its
rank order and 95% credible interval by determining the median
rank based on draws from the estimated effect size distributions
in Markov chain Monte Carlo simulations; displayed in
rankograms.40 The primary analysis was of the rate of severe
exacerbations, using data from all studies. We also carried out
analyses for the composite of moderate or severe exacerbations
combined, when both were reported. Preplanned subgroup
analyses were based on risk of bias assessment, asthma severity41
(based on prestudy treatment step1), study size, and duration of
intervention. Additional sensitivity analyses were done only
with non-imputed data (that is, excluding studies in which
numbers of exacerbations or patient years were not reported)
and with exclusion of open label studies.
We estimated heterogeneity between trials from the median of
the posterior distribution of the between trial variance τ2.42 Such
heterogeneity was considered to be low if τ2 estimates were
around 0.04, moderate if estimates approached 0.14, and large
if estimates were around 0.40. We assessed the consistency of
the model by comparing effect estimates derived through a
meta-analysis including only direct comparisons between pairs
of treatments, with the indirect effect estimates derived through
a network-meta analysis excluding the respective direct
comparison. We applied this procedure to all existing pairwise
comparisons in the analysis dataset. The network was regarded
as consistent when fewer than 5% of the differences between
direct and indirect estimates differed from zero.
WinBUGS 1.4.3 was used for the Markov chain Monte Carlo
simulations, Stata 12 for data preparation and post-processing
of simulation results, and SAS 9.3 for evaluation of rankograms.
Results
From the Cochrane reviews18-32 we identified 4851 records and
assessed 170 full text reports, of which 70 met our inclusion
criteria (fig 1⇓). We excluded four strategies from
analysis—cromoglycate,43 theophylline,44 azithromycin add-on
treatment,45 and combined inhaled corticosteroids, long acting
β agonists, and theophylline46—as they were identified as a
strategy in only one eligible trial. Six reports yielded data that
could not be synthesised, mainly because of lack of data on
exacerbations47-49 and patient years.50-52 Overall, 64 reports
describing 66 trials containing 59 622 patient years were
included in the analysis (also see web extra table
S1).4-6 8 9 11 44 53-108 Of the 13 corresponding authors contacted,
three provided additional data.
The intervention lasted approximately six months in more than
half of the reports (37/64, 58%), one year in 25 (39%), and more
than one year in only two.
Classification of treatment strategies
A total of 16 interventions were analysed (table⇓ and fig 2⇓):
regular short or long acting β agonists; leukotriene receptor
antagonists; and low dose inhaled corticosteroids (the reference
strategy) or high dose inhaled corticosteroids separately or
combined with regular short or long acting β agonists or with
leukotriene receptor antagonists. For combination therapy
(combined inhaled corticosteroids and long acting β agonists
in a single inhaler), we identified four strategies: combined fixed
dose treatment with low or high steroid doses and short acting
β agonists as reliever; combined adjustable maintenance dose
and short acting β agonists as reliever, in which maintenance
therapy was adjusted by either the doctor or the patient; and
combined maintenance and reliever therapy, in which the
combined inhaler was prescribed for both fixed maintenance
dosing and “as needed” reliever. Some studies compared the
index intervention with placebo, others to current guidelines
(best practice). Someminor treatment variations were included:
combined fixed dose treatment with as needed long acting β
agonists89 was included in combined fixed dose treatment, and
combined fixed dose treatment plus additional maintenance
inhaled corticosteroids with as needed short acting β agonists83
was included in combined fixed dose treatment with high dose
steroids.
Risk of bias
Poor reporting hampered complete assessment of risk of bias,
with 179/448 (40%) of the items classified as unclear (see web
extra table S2). In about 30% of the trials the risk of selection
bias (sequence generation and allocation concealment) was
deemed to be low. Twenty two per cent (14/64) of the trials
were deemed to be at high risk of bias because of problems with
blinding. To deal with this we performed an additional
sensitivity analysis. Incomplete outcomeswere tackled relatively
well, with approximately 80% assessed as being at low risk of
bias. Although after 2005 most trials were registered, they were
not all assessed as being at low risk of selective outcome
reporting, as some trials were registered retrospectively or
outcome variables were not registered before the start of the
trial. All reports except two106 107 were linked with the
pharmaceutical industry through authorship (52/64), sponsorship
or funding (56/64), or both (45/64). Funnel plots of all direct
comparisons with five or more studies did not show clear
evidence of small study bias (see web extra figure S3), although
assessment was hampered by sparse data: no direct comparisons
concerned 10 or more studies.
Severe exacerbations
We analysed 57 trials, including 53 309 patient years, for severe
exacerbations. Low dose inhaled corticosteroids (the reference
strategy) were superior to all other single agent strategies in
preventing severe exacerbations (fig 3⇓). The rate ratio for
placebo compared with low dose inhaled corticosteroids was
4.19 (95% credible interval 2.87 to 6.16). For preventing severe
exacerbations, only combined maintenance and reliever
treatment and combined fixed dose treatment performed
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significantly better than low dose inhaled corticosteroids, with
rate ratios of 0.44 (0.29 to 0.66) for combined maintenance and
reliever treatment and 0.51 (0.35 to 0.77) for combined fixed
dose treatment (fig 3). All other treatment strategies that used
combined inhaled corticosteroids and another agent, whether
by single or separate inhalers, tended to perform better than low
dose inhaled corticosteroids, although the difference was not
statistically significant. Data for exacerbation rates without
imputation were available for 45 trials (see web extra figure
S1); results were largely similar to the primary analysis, although
in severe exacerbations the difference between the common
comparator and combined fixed dose treatment was no longer
significant (0.63, 0.40 to 1.02).
Figure 3 also shows the estimated ranks of effectiveness for all
strategies, with associated 95% credible intervals. The
rankograms (fig 4⇓) show the probability of the effectiveness
of each strategy, ordered from the highest rank (combined
maintenance and reliever treatment and combined fixed dose
treatment) to the lowest rank (placebo).
We carried out preplanned stratified analyses based on risk of
bias assessment, study duration, study size, and prestudy
treatment step1 (see web extra figures S2 A-D), and additional
sensitivity analyses excluding studies that reported non-weighted
exacerbation rates (web extra figure S2 E) and unblinded studies
(web extra figure S2 F). These analyses did not show clear
differences from the primary analysis; eight out of 17 trials that
studied combined maintenance and reliever treatment
(containing 2656/8174 patient years) were excluded in this
sensitivity analysis, but similar rate ratios and rank orders were
observed. Some of the sensitivity analyses (for example, in
studies of more than 30 weeks’ duration) were hampered by
small numbers of events, resulting in wide credible intervals.
The estimate of between study variance (heterogeneity) was
moderate; τ2=0.102. For five out of 31 comparisons (inhaled
corticosteroids versus inhaled corticosteroids and long acting
β agonists, inhaled corticosteroids versus combinedmaintenance
and reliever treatment, inhaled corticosteroids and regular short
acting β agonists versus regular short acting β agonists,
combined fixed dose treatment versus combined maintenance
and reliever treatment, and regular long acting β agonists versus
regular short acting beta agonists) we found statistical evidence
for inconsistency between direct and indirect comparisons (fig
5⇓), predominantly in direct comparisons including only one
or two studies.
Composite of moderate or severe
exacerbations
For the composite of moderate or severe exacerbations, we
analysed 61 trials including 39 237 patient years (fig 3).
Although point estimates for rate ratios differed from those for
severe exacerbations, and credible limits were narrower—for
example, combined maintenance and reliever treatment 0.54
(95% credible interval 0.42 to 0.69) and combined fixed dose
treatment 0.68 (0.54 to 0.85)—overall trends were similar.
Figure 4 shows rankograms for the composite of moderate or
severe exacerbations, with combined maintenance and reliever
treatment ranking highest. Heterogeneity was low; τ2=0.070.
For two out of 33 comparisons (inhaled corticosteroids versus
high dose inhaled corticosteroids with regular long acting β
agonists and high dose inhaled corticosteroids with regular long
acting β agonists versus combined maintenance and reliever
treatment, we found statistical evidence for inconsistency
between direct and indirect comparisons (fig 6⇓).
Safety outcomes
Figure 7⇓ shows the risk ratios and the probability based rank
order with corresponding 95% credible intervals for withdrawal
as a result of adverse events for each strategy. Best practice had
the lowest rate of withdrawals due to adverse events. Combined
maintenance and reliever treatment was also associated with
significantly fewer withdrawals because of adverse events
compared with low dose inhaled corticosteroids. There was little
variation in withdrawal rates between the other treatment
strategies and no statistically significant differences from the
reference strategy. These results were largely confirmed by total
number of withdrawals (fig 7). (See web extra table S3 for
reported harms.)
Discussion
The purpose of this systematic review and networkmeta-analysis
was to identify all commonly used strategies for the prevention
of exacerbations of chronic asthma, estimate their efficacy and
safety compared with low dose inhaled corticosteroids, and
order them by rank. Our primary analysis shows that both
combined inhaled corticosteroids and long acting β agonists as
maintenance and reliever treatment and combined inhaled
corticosteroids and long acting β agonists as fixed dose treatment
significantly reduced the risk of severe exacerbations compared
with low dose inhaled corticosteroids alone, with the
combination strategies having similar rate ratios and a similar
ranking in the probability analysis. Other strategies that included
more than one agent performed similarly to each other compared
with low dose inhaled corticosteroids, and were not statistically
worse than combined maintenance and reliever treatment or
combined fixed dose treatment. All combined strategies
outperformed single agent strategies of regular leukotriene
receptor antagonists or long acting β agonists. When the total
exacerbation burden was considered, using studies that reported
bothmoderate and severe exacerbations, combinedmaintenance
and reliever treatment ranked highest, approximately halving
the risk of exacerbations compared with low dose inhaled
corticosteroids. These results provide an overview of efficacy
of all common treatment regimens in the prophylaxis of asthma
exacerbations, which can be used as a starting point in clinical
practice.
Comparison with other studies
Our approach is novel in that it includes all published treatment
options in a single analysis, allowing quantitative ranking of all
the available evidence. Our findings confirm and extend
previous focused studies based on direct pairwise comparisons
of treatments. Two meta-analyses, a Cochrane review25 and an
industry sponsored analysis,109 favoured combined maintenance
and reliever treatment over specific comparators in reducing
severe exacerbations, including combined fixed dose treatment.
In the more extensive analysis of the present study, apart from
combined maintenance and reliever treatment and combined
fixed dose treatment, treatment strategies involving an inhaled
corticosteroid and another agent, whether in one device or two
devices, did not perform statistically significantly better than
our reference strategy, low dose inhaled corticosteroids. The
combined strategies performed equally well in preventing severe
exacerbations, an observation challenging a previous
meta-analysis of six studies, four of which were of 4-12 weeks’
duration.22 The meta-analysis concluded that the addition of
long acting β agonists to inhaled corticosteroids was favoured
over the addition of leukotriene receptor antagonists. In our
network meta-analysis, in which inhaled corticosteroid doses
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were classified as either low or moderate or high, we were
unable to confirm the previously reported positive effects of
increasing doses of inhaled corticosteroids in preventing
exacerbations.13 This is probably because in the included studies
the intervention of inhaled corticosteroid dose was typically
double that of the control inhaled corticosteroid dose, but both
doses may still have fallen within either our low dose or
moderate or high dose inhaled corticosteroid categories. Another
explanationmay be underlying differences in the original patient
populations. For example, there were differences in baseline
forced expiratory volume in one second (%) predicted between
patients in trials using high dose inhaled corticosteroids (median
72.2%, range 64.0-95.5%, interquartile range 69.0-75.4%) and
those using low dose inhaled corticosteroids (median 82.3%,
range 65.6-102.0%, interquartile range 75.4-88.8%). For severe
exacerbations as well as the composite of moderate or severe
exacerbations, low dose inhaled corticosteroids seemed to be
superior to regular short or long acting β agonists or to
leukotriene receptor antagonists alone, a finding that has been
observed previously.20 27
Strengths and limitations of this study
Our study has several strengths. Firstly, network meta-analysis
allowed comparison of all available strategies in a single
analysis, giving a combined total of 59 622 patient years of
treatment, rather than separate and disconnected meta-analyses
for individual pairs of treatments. By conducting a network
meta-analysis we were able to provide a formal rank order for
treatment strategies by their capacity to reduce exacerbations,
while capturing the imprecision of such rankings.
Secondly, we carefully developed the inclusion criteria for trials.
As exacerbations are relatively infrequent outcomes, we
restricted our study to reports with treatment durations of at
least 24 weeks (close to six months) to reflect the effects of long
term treatment in a variable disease. In several other
meta-analyses with exacerbations as an outcome variable, the
bulk of the evidence has originated from studies with durations
of intervention between three and six months, a relatively short
period as asthma treatment usually lasts for years, and in clinical
trials the effects of treatment seem to decrease with increasing
duration of intervention.13 17 22 24
Thirdly, where the interpretation of previous reviews was
hampered by pooling of data based on variously defined
exacerbations, we applied predetermined standardised definitions
based on those of the American Thoracic Society/European
Respiratory Society.17 This allowed a comprehensive cross
comparison of all studies. As recommended by the report of the
American Thoracic Society/European Respiratory Society, we
did not attempt to classify mild exacerbations. The composite
of moderate or severe exacerbations combined can thus be
regarded for clinical interpretation as representing the total
number of exacerbations. Thirty nine studies measured severe
exacerbations, but only 17 were consistent with this current
definition. In addition, we found that exacerbation outcomes,
particularly for severe exacerbations, were reported in several
ways (number of exacerbations, number of patients with at least
one exacerbation, and weighted or non-weighted exacerbation
rates (annually or in other time frames)), underscoring the value
of our recalculations to reliably compare strategies.
We acknowledge the following limitations to our work. Firstly,
the criteria for selection of strategies was based on existing
Cochrane reviews and our own searches to update those reviews,
so the comprehensiveness of our study depends on the adequacy
of the original Cochrane research questions and search terms.
Secondly, we did not include unpublished or premarketing
studies from drug regulatory agencies such as the Food and
Drug Administration and European Medicines Agency; this
might have led to a reporting bias.110However, since all included
studies were related to the pharmaceutical industry, differential
reporting bias may have been reduced.111 Thirdly, there was
heterogeneity between trial populations—for example, in
baseline lung function. This might explain some of the observed
inconsistency and heterogeneity for the primary outcome of
severe exacerbations. If this were the case, we would expect the
same pattern in the analysis of the secondary composite outcome
of moderate or severe exacerbations. However, this analysis
yielded low heterogeneity and little evidence for inconsistency.
Moreover, inconsistencies were nearly exclusively observed in
direct comparisons with only one or two trials. Therefore we
believe that the patients included in our component trials were
sufficiently similar to meet the similarity assumptions for
network meta-analysis. Finally, the generalisability of the
findings is limited by the original trial inclusion criteria—for
example, many studies required non-smokers with significant
bronchodilator reversibility, so participants were not necessarily
representative of the general population with asthma.112
However, a requirement for an exacerbation in the previous 12
months, seen in more recent studies, is not regarded as a
limitation if the aim of the study was to reduce exacerbations.
Policy implications
Low dose inhaled corticosteroids are highly effective in reducing
severe asthma exacerbations, with patients receiving placebo
having a rate ratio of over 4 for experiencing a severe
exacerbation within six months. In comparison with low dose
inhaled corticosteroids, we identified combined maintenance
and reliever treatment as the highest ranked strategy for
preventing total exacerbations (composite of moderate or
severe), and equally ranked with combined fixed dose treatment
for preventing severe exacerbations. It has been proposed that
the mechanism for greater reduction of exacerbations with the
combined maintenance and reliever treatment strategy is from
either an early (patient initiated) up-titration of inhaled
corticosteroids and β agonist dose as soon as asthma symptoms
worsen, thus avoiding delays by doctors or patients, or greater
adherence with drugs containing inhaled corticosteroids. Both
of these ideas was supported by one of the included studies,
independent of pharmaceutical companies, using real time
electronic monitoring of all inhalers supports.107Although some
of the studies of combined maintenance and reliever treatment
included in the present analysis were unblinded, a sensitivity
analysis omitting unblinded trials (eight trials with 2656 patient
years of the combined maintenance and reliever treatment
strategy), showed similar results to the primary analysis.
All strategies consisting of inhaled corticosteroids together with
another agent had rate ratios below 1, suggesting better
performance than inhaled corticosteroids used alone, although
none of these differences, other than combined maintenance
and reliever treatment and combined fixed dose treatment, were
statistically significant for severe exacerbations. This does not,
however, allow the conclusion that these two strategies are
statistically better than other combination strategies. Not
unexpectedly, the rank numbers of these inhaled corticosteroids
combined with other agent strategies have broad credible
intervals and therefore may be regarded as equally effective in
preventing exacerbations. Therefore, a choice of any treatment
containing inhaled corticosteroids should be based on other
factors, such as impact on control of asthma symptoms,113 patient
or doctor preference, cost, availability, or potential for side
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effects. Monotherapy with agents other than inhaled
corticosteroids was not as effective in preventing exacerbations.
Subsequent network meta-analysis may show whether this also
holds for outcomes such as symptoms, lung function, and cost,
although the heterogeneity between studies in reporting of such
outcomes is even more noticeable than for exacerbations, and
there is increasing recognition of discordance between current
asthma control and adverse outcomes such as exacerbations.17
In terms of safety, it was not surprising that the best practice
strategy had the lowest withdrawal rate. This intervention, in
which the patient and practitioner are free to choose the drug
or regimen that they believe is superior or safer than others, is
only possible in open label trials. In an open label study, both
patients and practitioners are less likely to withdraw from a
familiar treatment (best practice) than from an unfamiliar (new)
treatment. In contrast with best practice, all other interventions
(including combined maintenance and reliever treatment and
combined fixed dose treatment) were found in both open label
and double blind trials. Withdrawal rates are typically higher
in double blind trials. Combined maintenance and reliever
treatment ranked second only to current best practice in the
safety measures. For other strategies, withdrawals as a result of
adverse events were not significantly different from those of
low dose inhaled corticosteroids; total numbers of withdrawals
were significantly higher with placebo and with long acting β
agonists compared with low dose inhaled corticosteroids.
Conclusions
This comprehensive networkmeta-analysis shows that combined
inhaled corticosteroids and long acting β agonists as
maintenance and reliever treatment has a good safety profile
and is better in preventing total asthma exacerbations than low
dose inhaled corticosteroids alone. Treatment with a combined
fixed dose was equally effective at reducing severe
exacerbations. All combinations of inhaled corticosteroids and
other agents seem to be similarly effective and not significantly
better than low dose inhaled corticosteroids. These results
suggest that, when low dose inhaled corticosteroids are not
sufficiently effective, combined maintenance and reliever
treatment or combined fixed dose treatment may be preferred
for the reduction of exacerbations.
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Table
Table 1| Identified strategies for maintenance treatment of asthma
Daily dose (µg)Medium/high dose ICS strategyDaily dose (µg)Strategy and generic name
SABA:
——NSSalbutamol
——NSTerbutaline
LABA*:
——NSFormoterol
——NSSalmeterol
LTRA*:
——12Montelukast
ICS*:
>500ICS H*200-500Beclometasone
>400ICS H*200-400Budesonide
>250ICS H*100-250Fluticasone
>160ICS H*80-160Ciclesonide
>400ICS H*200-400Mometasone
Combined as above, in separate inhalersICS+SABA*
Combined as above, in separate inhalersICS H+SABA*
Combined as above, in separate inhalersICS+LABA*
Combined as above, in separate inhalersICS H+LABA*
Combined as above, in separate inhalersICS+LTRA*
COMBI FIX*
>200/12COMBI FIX H*100/6-200/12Beclometasone/formoterol
>400/12COMBI FIX H*200/6-400/12Budesonide/formoterol
>250/50COMBI FIX H*250/50Fluticasone/salmeterol
>400/20COMBI FIX H*100/5-400/20Mometasone/formoterol
As COMBI FIX, but dose regularly adapted by doctor or patient, guided by symptomsCOMBI AMD*
As COMBI FIX, but combination agent also used as relief or rescue agent when warrantedCOMBI MAR
Doctors requested to treat patients according to current or local asthma treatment guidelinesBest Practice
Non-active comparatorPlacebo
ICS=inhaled corticosteroids; SABA=short acting β agonists, regular use; NS=not specified; LABA=long acting β agonists, regular use; LTRA=leukotriene receptor
antagonist; H=high daily dose inhaled corticosteroids (>500 µg beclometasone equivalents); COMBI=combined ICS and LABA in single inhaler; COMBI FIX=COMBI
in fixed daily dose; COMBI AMD=COMBI in adjustable maintenance dose; COMBI MAR=COMBI as maintenance and reliever treatment.
ICS doses by approximation, for analysis dose equivalents of beclometasone was used as stated in methods section.
*Relief or rescue drug with short acting β agonists allowed.
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Figures
Fig 1 Flow chart of study selection
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Fig 2 Overview of treatment strategies, with lines representing direct (head to head) comparisons; surface areas of circles
proportional to number of patients identified in strategy. Numbers in lines are number of direct comparisons. COMBI=combined
inhaled corticosteroid (ICS) and long acting β agonist (LABA) in single inhaler; COMBI MAR=COMBI as maintenance and
reliever treatment; COMBI FIX=COMBI in fixed daily dose; COMBI AMD=COMBI in adjustable maintenance dose; H=high
dose; LABA=long acting β agonists, regular use; LTRA=leukotriene receptor antagonist; SABA=short acting β agonists,
regular use
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Fig 3 Forest plot showing asthma exacerbation rate ratios and median ranks with corresponding 95% credible intervals for
each strategy compared with low dose inhaled corticosteroids (ICS). COMBI=combined ICS and long acting β agonist
(LABA) in single inhaler; COMBI MAR=COMBI as maintenance and reliever treatment; COMBI FIX=COMBI in fixed daily
dose; COMBI AMD=COMBI in adjustable maintenance dose; H=high dose; LABA=long acting β agonists, regular use;
LTRA=leukotriene receptor antagonist; SABA=short acting β agonists, regular use
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Fig 4 Rankograms showing probability (percentage) of each strategy having each specific rank (1-16) for effectiveness in
the prevention of severe and composite of moderate or severe asthma exacerbations. Strategies ordered by rank from top
left to bottom right. In severe exacerbations, combined inhaled corticosteroids (ICS) and long acting β agonists (LABA) in
single inhaler as maintenance and reliever treatment (COMBI MAR), and in fixed daily dose (COMBI FIX) have highest
probabilities to be ranked first and placebo the highest probability to be ranked last. COMBI AMD=combined ICS and LABA
in adjustable maintenance dose; H=high dose; LTRA=leukotriene receptor antagonist; SABA=short acting β agonists,
regular use
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Fig 5 Difference in estimated treatment effects for severe asthma exacerbations between direct comparison (based on
classic meta-analysis) and indirect estimate from multi-treatment comparison (without respective direct comparison).
Difference on log-relative risk scale for rates; variance constructed by adding up variances of both estimates. Best practice
is an open label comparator in which practitioners are encouraged to treat patients according to current treatment guidelines.
COMBI=combined ICS and long acting β agonist (LABA) in single inhaler; COMBI MAR=COMBI as maintenance and
reliever treatment; COMBI FIX=COMBI in fixed daily dose; COMBI AMD=COMBI in adjustable maintenance dose; H=high
dose; LABA=long acting β agonists, regular use; LTRA=leukotriene receptor antagonist; SABA=short acting β agonists,
regular use
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Fig 6 Difference in estimated treatment effect for composite of moderate or severe asthma exacerbations between direct
comparison (based on classic meta-analysis) and indirect estimate from multi-treatment comparison (without respective
direct comparison). Difference on log-relative risk scale for rates; variance constructed by adding up variances of both
estimates. Best practice is an open label comparator in which practitioners are encouraged to treat patients according to
current treatment guidelines. COMBI=combined ICS and long acting β agonist (LABA) in single inhaler; COMBI MAR=COMBI
as maintenance and reliever treatment; COMBI FIX=COMBI in fixed daily dose; COMBI AMD=COMBI in adjustable
maintenance dose; H=high dose; LABA=long acting β agonists, regular use; LTRA=leukotriene receptor antagonist;
SABA=short acting β agonists, regular use
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Fig 7 Forest plot showing withdrawals as a result of adverse events and total number of withdrawals compared with low
dose inhaled corticosteroids (ICS). Best practice is an open label comparator in which practitioners are encouraged to treat
patients according to current treatment guidelines. COMBI=combined ICS and long acting β agonist (LABA) in single inhaler;
COMBI MAR=COMBI as maintenance and reliever treatment; COMBI FIX=COMBI in fixed daily dose; COMBI AMD=COMBI
in adjustable maintenance dose; H=high dose; LABA=long acting β agonists, regular use; LTRA=leukotriene receptor
antagonist; SABA=short acting β agonists, regular use
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